Overview

• President Trump announced potential 200% tariffs on imported pharmaceuticals if companies do not relocate production to the United States within 12 to 18 months.
• Mexico’s drug exports to the US climbed 88% since 2019, reaching over $1 billion last year with electrolytes leading at $385 million.
• Canifarma and Amelaf warn that USMCA rules bar punitive tariffs on member countries and stress that building new drug plants requires four to seven years.
• Novartis Mexico views the tariff proposal as a negotiating tactic and is collaborating with government initiatives to enhance local regulatory and clinical research capacity.
• Cofepris has slashed clinical trial approval times from as long as 12 months to around 40 days under Plan México to attract further pharmaceutical investment.